On June 6, 2025, Arcturus Therapeutics Holdings Inc. held its annual stockholder meeting where shareholders elected nine directors, approved executive compensation, and ratified the appointment of Deloitte as the independent accounting firm, with 22,006,524 shares represented at the meeting.